Clinical Trial

Differential Thrombogenesis by EPA and DHA Mediated by HDL

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this study is to learn more about omega-3 polyunsaturated fatty acids supplementation on blood lipid profile and platelets in patients with high cholesterol levels. The purpose of this research is to gather information on the safety and effect of two different fish oils, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Participants will: Visit the clinic 3 times during study checkups, tests and blood collection. Randomized to either the EPA or the DHA supplementation group. Be given a 28-day food and activity log.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-02; most recent amendment 2025-09-25.
Status change: Not Yet Recruiting → Recruiting 2025-09-25
Trial Details
NCT Number NCT06494488
Lead Sponsor The Miriam Hospital
Collaborators: National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
Conditions Lipid Metabolism Disorders, Hypertriglyceridemia
Enrollment 80 participants
Start Date 2025-07-10
Primary Completion 2027-08-01 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-10-01